Company Description
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.
The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025.
The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Asset Management |
| Sector | Financials |
| Employees | 52 |
| CEO | Douglas Onsi |
Contact Details
Address: 47 Thorndike Street, Suite B1-1 Cambridge, Massachusetts 02141 United States | |
| Phone | 617 714 0360 |
| Website | leaptx.com |
Stock Details
| Ticker Symbol | CYPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001509745 |
| CUSIP Number | 52187K200 |
| ISIN Number | US52187K2006 |
Key Executives
| Name | Position |
|---|---|
| Douglas Onsi | Chief Executive Officer |
| Douglas Onsi | Chief Financial Officer |